Nurix Therapeutics, Inc. ($NRIX) announced an update on their ongoing clinical study. Study Overview: Nurix Therapeutics, Inc. (NRIX) is currently ...

Following the expanded approval, the accelerated approval for the later-line CLL/SLL was converted to a traditional approval.

ORLANDO -- Patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) lived significantly longer without disease progression when treated with the Bruton's ...

Pirtobrutinib is now FDA-approved for relapsed/refractory CLL/SLL after prior covalent BTK inhibitor therapy, following its 2023 accelerated approval. The BRUIN-CLL-321 trial showed pirtobrutinib ...

Lilly’s Jaypirca scores big in first-line CLL/SLL, cutting progression risk by 80% and challenging rival BTK inhibitors.

Eli Lilly and Company (NYSE:LLY) is one of the best pharma stocks to invest in. On December 7, Eli Lilly and Company ...

The presentation and publication of the BRUIN CLL-314 trial followed the FDA’s December 3 decision to expand approval for ...

ORLANDO -- In a phase III trial with potential practice-changing implications, the non-covalent Bruton's tyrosine kinase (BTK ...

LBA-3: Pirtobrutinib vs Bendamustine Plus Rituximab (BR) in Patients with CLL/SLL: First Results from a Randomized Phase III ...

Eli Lilly's fast-growing blood cancer drug Jaypirca has bagged a new FDA approval as an earlier treatment for relapsed or ...

The recommendation to add COPIKTRA ( duvelisib) to the NCCN Guidelines is based on the broad body of evidence and uniform consensus ( > 85% support of the NCCN Panel) that intervention is appropriate.